Marstacimab

Key takeaways

Marstacimab belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Marstacimab to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Marstacimab from memory before moving on to harder problems.

Reference excerpt

Marstacimab, sold under the brand name Hympavzi, is a monoclonal antibody medication used for the treatment of hemophilia A and hemophilia B. It is a tissue factor pathway inhibitor antagonist. It was developed by Pfizer. Marstacimab is a new type of medication that, rather than replacing a clotting factor, works by reducing the amount, and therefore, the activity of, the naturally occurring anticoagulation protein called tissue factor pathway inhibitor. This increases the amount of thrombin, an enzyme that is critical in blood clotting, that is generated. This is expected to reduce or prevent the frequency of bleeding episodes. The most common side effects include injection site reactions, headache, and itching (pruritis). Marstacimab was approved for medical use in the United States in October 2024, and in the European Union in November 2024. The US Food and Drug Administration considers it to be a first-in-class medication.

Medical uses Marstacimab is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in people aged twelve years of age and older with hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or hemophilia B (congenital factor IX deficiency) without factor IX inhibitors.

Side effects The US prescription label for marstacimab contains warnings and precautions about circulating blood clots (thromboembolic events), hypersensitivity, and embryofetal toxicity. The most common side effects include injection site reactions, headache, and itching (pruritis).

History The US Food and Drug Administration (FDA) approval of marstacimab is based on the BASIS study (NCT03938792), an open-label, multi-center study in 116 adult and pediatric male participants with either severe hemophilia A or severe hemophilia B, both without inhibitors. For the first six months of this study, participants received treatment with replacement factor either on-demand (33 participants) or prophylactically (83 participants). These participants then received marstacimab prophylaxis for twelve months. The primary measure of efficacy of marstacimab was the annualized bleeding rates of treated bleeds. In the participants receiving on-demand factor replacement during the first six months of the study, the estimated annualized bleeding rate was 38 compared to the estimated annualized bleeding rate during treatment with marstacimab of 3.2, showing that marstacimab was superior to on-demand factor replacement. In the initial six-month period during which participants received prophylactic factor replacement, the estimated annualized bleeding rate was 7.85 and was 5.08 during the subsequent twelve months on marstacimab prophylaxis, showing that marstacimab provided similar bleeding rates. The FDA approved marstacimab based on evidence from a one clinical trial, BASIS (NCT03938792), which included 116 adults and pediatric participants twelve years of age and older with hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors and hemophilia B (congenital factor IX deficiency) without factor IX inhibitors. The trial was conducted at 52 sites in 19 countries in Bulgaria, Canada, China, Croatia, France, Hong Kong, India, Italy, Japan, Republic of Korea, Mexico, Oman, Russian Federation, Saudi Arabia, Serbia, South Africa, Spain, Turkey, and the United States. There was one participant from the United States and 115 participants from outside the United States enrolled in the trial. The FDA granted the application for marstacimab orphan drug designation for this application. The FDA granted the approval of Hympavzi to Pfizer Inc.

Society and culture

Legal status In September 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Hympavzi, intended for prophylaxis of bleeding episodes in people aged twelve years of age and older, weighing at least 35 kilograms (77 lb), who have severe hemophilia A or B. The applicant for this medicinal product is Pfizer Europe Ma EEIG. Marstacimab was authorized for medical use in the European Union in November 2024. The US Food and Drug Administration approved marstacimab in October 2024, for people aged twelve years of age and older with hemophilia A and B without inhibitors (to prevent or reduce bleeding episodes).

Names Marstacimab is the international nonproprietary name. Marstacimab is sold under the brand name Hympavzi.

References

External links Clinical trial number NCT03938792 for "Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B" at ClinicalTrials.gov

Worked examples

Example 1 — a first encounter with Marstacimab

Start with the simplest possible case. Write down what Marstacimab claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Marstacimab before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Marstacimab ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Marstacimab

In research: Marstacimab appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Marstacimab in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Marstacimab is common in secondary-school and first-year university syllabi. It links to neighbouring topics Antihemorrhagics, Drugs developed by Pfizer, Monoclonal antibodies, so understanding it makes those chapters shorter.
In everyday life: Look for Marstacimab outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

How to study Marstacimab in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Marstacimab means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Marstacimab out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Marstacimab in simple terms?

Marstacimab, sold under the brand name Hympavzi, is a monoclonal antibody medication used for the treatment of hemophilia A and hemophilia B. It is a tissue factor pathway inhibitor antagonist.

Why does Marstacimab matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Marstacimab?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Marstacimab.